CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy: 5-year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer Mathematical modelling of endovascular drug delivery: balloons versus stents Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: A review
|<<... 167 168 169 170 171 172 173 ...>>|

Original Research2018 Apr 9;11(7):665-674.

JOURNAL：JACC Cardiovasc Interv. Article Link

Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost

Kwok CS, Rao SV, Potts JE et al. Keywords: cost; percutaneous coronary intervention; predictors; readmission

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top